A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies

BACKGROUND: A major perspective for the use of circulating tumor DNA (ctDNA) in the clinical setting of non-small cell lung cancer (NSCLC) is expected as predictive factor for resistance and response to EGFR TKI therapy and, especially, as a non-invasive alternative to tissue biopsy. However, ctDNA...

Descripción completa

Detalles Bibliográficos
Autores principales: Jensen, Steffen Grann, Epistolio, Samantha, Madsen, Cesilie Lind, Kyneb, Majbritt Hauge, Riva, Alice, Paganotti, Alessia, Barizzi, Jessica, Petersen, Rasmus Koefoed, Børgesen, Michael, Molinari, Francesca, Boldorini, Renzo, Lorenzen, Jan, Sørensen, Erik, Christensen, Ulf Bech, Høgdall, Estrid, Frattini, Milo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224962/
https://www.ncbi.nlm.nih.gov/pubmed/34166445
http://dx.doi.org/10.1371/journal.pone.0253687

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224962/
https://www.ncbi.nlm.nih.gov/pubmed/34166445
http://dx.doi.org/10.1371/journal.pone.0253687

Ejemplares similares